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OBJECTIVES: The objective of this study is to evaluate the cost-effectiveness of 
aflibercept compared to ranibizumab for the treatment of wet age-related macular 
degeneration (wAMD) in Turkey. METHODS: A Markov model consisting of six health 
states on vision impairment as “no vision impairment; mild vision impairment; 
moderate vision impairment; severe vision impairment; total blindness; death” 
with a 20-year timeframe was adapted to the Turkish setting through an expert 
panel. Clinical transition inputs between visual acuity states and safety data were 
mainly derived from the results of Phase III VIEW-1 and VIEW-2 trials. Economic 
inputs were based on the expert opinion addressing local treatment, monitoring and 
adverse event management algorithms. The primary and secondary endpoints for 
the study were blind years and QALYs, respectively. Analyses were conducted from 
the Turkish Payer Social Security Institution perspective. All costs were calculated in 
Turkish Liras (TL) and then converted to USD using TL/USD currency rate as 2,1 (mid-
2014). RESULTS: Aflibercept was associated with 6,614 blind years and 4,805 QALYs, 
while ranibizumab was associated with 6,599 blind years and 4,810 QALYs; resulting 
in total of 0,015 more blind years and 0,005 less QALYs for aflibercept compared 
with ranibizumab in the treatment of wAMD. Total costs associated with aflibercept 
and ranibizumab were 25.954 USD and 30.311 USD respectively; resulting with a 
total of 4.357 USD less costs for aflibercept compared with ranibizumab, driven 
by savings in medication, administration and monitoring costs. CONCLUSIONS: 
Aflibercept was found as the cost-effective treatment option when compared with 
ranibizumab in the treatment of wAMD in Turkish setting. Aflibercept was associ-
ated with significant less cost leading to savings in medication, administration and 
monitoring costs; while being clinically equivalent with negligible benefits as blind 
years averted and QALYs gained in comparison with ranibizumab.
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OBJECTIVES: Routine clinical practice in UK patients with severe dry eye disease 
is a combination of artificial tears (AT) and ocular lubricant ointments. This study 
aims to assess the cost-effectiveness to the UK NHS of the addition of Ikervis® 
(Ciclosporin A; CsA) to routine practice for patients who have not adequately 
responded to therapy. METHODS: Using a Markov framework, future health effects 
and costs were modeled. Eligible patients receive six months therapy with Ikervis® 
plus AT and ocular lubricants or AT and ocular lubricants without CsA. Upon com-
pletion, those who respond sufficiently remain on CsA treatment for the dura-
tion of the response, achieving a higher quality of life (HRQoL) and lower AT use. 
Incremental cost effectiveness ratios (ICER) were expressed in GBP (£) per QALY 
gained with costs and health effects discounted at 3.5% over a lifetime time hori-
zon. Deterministic and probabilistic sensitivity analyses were employed to assess 
the effect of uncertainty on the model. Scenario analyses including less stringent 
improvement criteria, alternative approaches to deriving response stratified utility 
values and a shorter initial trial period were performed. RESULTS: Compared with 
AT alone, Ikervis® results in a lifetime cost to the UK NHS of £713 per patient, but 
offers an additional 0.04 QALYs. The ICER is £19,156/QALY gained. At a commonly 
accepted cost-effectiveness threshold of £30,000 per QALY, Ikervis® is cost-effective 
in 70.8% of simulations. Tornado analysis showed the model is most sensitive to 
the incremental benefit on patient’s long-term HRQoL associated with respond-
ing to therapy compared with non-response. CONCLUSIONS: The modelling study 
showed that from an NHS perspective, health gains can be achieved at a low cost. 
The Ikervis® ICERs are well below the NICE’s commonly accepted cost-effectiveness 
threshold of £30,000/QALY gained, indicating that Ikervis® in the target patient 
population would represent a cost-effective intervention in the UK.
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OBJECTIVES: To check prescribing pattern for glaucoma and to design a treatment 
guideline for POAG that is more cost effective from the perspective of a third party 
payer than the current practice based on real world evidence METHODS: A retrospec-
tive descriptive study of glaucoma patients was carried out with the aid of data col-
lection form. The prices (95% CL) of antiglaucoma drugs were estimated from hospital 
price list and the 5 nearby community pharmacies. Eighty randomly selected case 
notes of glaucoma patients on therapy for at least 3 months were studied. Data col-
lected were the demographics and diagnosis, IOP per month and the drugs prescribed. 
A Stochastic Monte model based on the outcome and cost was constructed with the 
aid of vanguard studio 5.0 (Cary, North Carolina, USA). The outcome of the therapy 
which was entered as the proportion of patients whose IOPs were normal, reduced 
or either increased or unchanged per month of treatment. Sensitivity analysis was 
conducted by varying the input data by ±50%. RESULTS: The proportion of patients 
that IOP was checked regularly was low 26.76% .The commonly prescribed drugs 
were the beta blockers and carbonic anhydrase inhibitors. The current practice will 
cost USD430.86 (NGN 77,783.76) per patient per annum whereas the proposed guide-
line that result in improved outcome will cost USD 44.10 (NGN7, 953.12). Treatment 
guideline is absent in Standard treatment guideline of Nigeria CONCLUSIONS: The 
patients that IOP was checked regularly were low and multi therapy was prescribed 
at onset with the Beta blockers plus Carbonic anhydrase inhibitors. A cost savings of 
NGN69, 830.64 will be obtained by the proposed guideline for POAG per patient per 
annum thus it could be adopted after evaluation at several sites
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relative to ranibizumab and dexamethasone. Total costs associated with afliber-
cept, ranibizumab and dexamethasone were 4.260 USD, 5.219 USD and 1.631 USD 
respectively, resulting for the cost of aflibercept treatment being 959 USD lower 
compared to ranibizumab and 2.629 USD higher compared to dexamethasone. 
Aflibercept was dominant over ranibizumab. The ICER for aflibercept as compared 
to dexamethasone was calculated as 7.144 USD/QALY. CONCLUSIONS: For the 
treatment of CRVO in Turkish setting, aflibercept was found to be the dominant 
treatment option when compared with ranibizumab while being more effective 
and less costly. Compared with dexamethasone aflibercept was found as cost-
effective with an ICER of 7.144 USD, well below the willingness-to-pay threshold 
(GDP per capita „Ÿ 10.782 USD) for Turkey.
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OBJECTIVES: To assess the cost-effectiveness of secukinumab versus current 
therapies for plaque psoriasis in adults from the Canadian healthcare perspec-
tive. METHODS: A Markov model was designed to determine the cost-effectiveness 
of secukinumab 300mg for moderate to severe plaque psoriasis over a 10-year hori-
zon versus secukinumab 150mg, adalimumab, etanercept, infliximab, ustekinumab 
(45mg or 90mg), and standard of care (oral systemics, topicals, and phototherapy, 
SoC). Year 1 of the model consisted of 4-week cycles with 4 Psoriasis Area and 
Severity Index (PASI) response level-based health-states (PASI ≥ 90, 75-89, 50-74, 
and < 50). Years 2-10 used annual cycles, with 3 health-states (PASI ≥ 75, PASI <75, 
and death).  Decisions to switch to SoC were made at week 12 and 52, then annually. 
Efficacy data from a network meta-analysis informed first-year model transitions. 
Resource use, costs, and utilities were collected from clinical trials, published lit-
erature, expert opinion, and standard Canadian sources. RESULTS: The order of 
treatments by increasing quality-adjusted life years (QALYs) were: SoC, etanercept, 
adalimumab, ustekinumab 45mg, secukinumab 150mg, ustekinumab 90mg, secuki-
numab 300mg, and infliximab. The cost-effectiveness frontier showed etanercept 
was strongly dominated, while adalimumab, ustekinumab 45mg, secukinumab 
150mg and ustekinumab 90mg were weakly dominated by secukinumab 300mg. 
The ICER for secukinumab 300mg versus SoC was $87,368/QALY gained. The ICER for 
infliximab versus secukinumab 300mg was $1,039,403/QALY gained. Deterministic 
sensitivity analyses indicated the results are most sensitive to time horizon, cost 
of biologics, and utility values. The probabilistic sensitivity analysis demonstrated 
that at a willingness-to-pay threshold of ~$90,000/QALY, secukinumab 300mg has 
the highest probability of being the cost-effective option. CONCLUSIONS: For adults 
with moderate to severe plaque psoriasis, secukinumab 300mg was associated with 
increased QALYs at a lower incremental cost compared to etanercept, adalimumab, 
ustekinumab and secukinumab 150mg. For each QALY gained versus SoC, treatment 
with secukinumab costed an additional $87,368.
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OBJECTIVES: To report the cost per outcome of a robust model to deliver glaucoma 
examinations to older Philadelphians at community centers. METHODS: The cost-
outcome analysis was performed taking a health system perspective, with outcome 
defined as diagnostic yield (cases of glaucoma detected and cases of any ocular dis-
ease detected). Costs included supplies (slit lamp, visual field machine, handheld 
fundus camera, laptops, medical and office supplies), travel (van rental, fuel, main-
tenance, personnel mileage reimbursements), and personnel time (for examination, 
travel to sites, training, and supervision). Personnel time was captured by time and 
motion data collected during site visits. Costs of community health workers and 
medical assistants were based on regional 2013 US Bureau of Labor and Statistics (BLS) 
wage rates, and ophthalmologist wages were based on 2013 NIH salary cap. Wage rates 
for project supervisors were assumed to be 25% more than a medical assistant. Fringe 
benefits were added to all wage costs at 31% (BLS). RESULTS: 1649 participants were 
examined from 2012-2013, of whom 68% were females, 70% were African-Americans, 
and the mean age was 69 (SD 11). The mean total examination time was 56 minutes 
(SD 4). Visual field and physician consult were the most time-consuming steps (11-13 
minutes each). Glaucoma and angle closure represented 17% of the 2197 diagnoses 
made. Other diagnoses made included glaucoma suspect (16%), cataracts (52%), dia-
betic retinopathy (2%), and macular degeneration (1%). Examination and staff travel 
were the largest components of total costs at $67,018 and $24,340, respectively. The 
total program cost was $229,082 ($139/participant). The cost/case of glaucoma diag-
nosis (confirmed, suspected or angle-closure) was $550. The cost/case to detect any 
ocular disease was $104. CONCLUSIONS: The cost to deliver glaucoma examinations 
through this program is relatively low in relation to its diagnostic yield, however 
opportunities exist to improve efficiency of examination and travel.
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OBJECTIVES: The aim of the present study was to assess the diagnostic 
delay and the associated factors in patients with cutaneous malignant mela-
noma. METHODS: We carried out a survey including medical record analysis in 
patients diagnosed within five years with cutaneous malignant melanoma at the 
Pécs Dermatological Clinic (n= 362).The study investigated the diagnostic delay, its 
risk factors as clinical and histological characteristics of the tumor, and patients’ 
sociodemographic factors. Chi-square test, Mann-Whitney U test, and Kruskall-
Vallis test was used with 95% probability level (p< 0.05). RESULTS: 195 females and 
167 males participated in the investigation. The mean age was 54.5+/-14.8. Breslow 
tumor thickness was below 1 mm in 48.1% of patients and above 4 mm in 12.2% of 
patients. 35.1% of patients consulted a doctors six or more months later than the 
symptoms had appeared. The mean delay was 8.1+/-15.6 months. The prolonged 
delay resulted in more expressed tumor thickness (p= 0.027). Tumor thickness and 
delay showed no significant difference in the case of the tumor type and ulceration 
(p> 0.05). A higher proportion of women discovered the abnormality compared with 
men (65.2% versus 34.8%; p< 0.001). The latter subjects were informed by their rela-
tives to examine themselves. The most common site of prevalence was the lower 
limb in females (78.5% of cases); the trunk in males (61.3% of cases) (p< 0.001). 
The most common symptom observed by patients was the increase in lesion 
size (50.3%). Its prevalence on the lower limb (p= 0.01) and the increase in lesion 
size (p< 0.001) was associated with significantly longer delay. CONCLUSIONS: 
The study provides essential information for developing education campaigns in 
the future involving awareness promotion related to lesions perceived as minor 
significance. The present study emphasizes the importance of mindfulness and 
skills in the early detection of tumors. Prevention should be a decisive factor in 
primary care.
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OBJECTIVES: To evaluate measurement properties of the Psoriasis Symptom 
Inventory (PSI) in moderate/severe plaque psoriasis (PsO). METHODS: A second-
ary analysis of pooled data from a Phase III study of brodalumab in moderate to 
severe PsO patients (n= 661) was conducted. Outcome measures included: PSI (as 
a daily electronic diary), Psoriasis Area and Severity Index (PASI), static Physician’s 
Global Assessment (sPGA), involved body surface area (BSA), Dermatology Life 
Quality Index (DLQI), and the 36-item Health Survey version 2 (SF-36v2). Analyses 
included: confirmatory factor analysis (CFA) and Rasch analysis (dimensionality 
and item performance); Cronbach’s α (internal consistency); intraclass correla-
tion coefficients (ICCs) among patients with stable disease (test-retest reliabil-
ity); Spearman correlations (convergent validity); analysis of variance (known 
groups validity and ability to detect change); and agreement (Kappa, k) between 
PSI responders (PSI total score≤ 8 with no item score> 1) and PASI 75/90, sPGA 
0/1, and DLQI 0/1 responders. RESULTS: Results supported unidimensionality, 
good item fit, ordered responses, and combining of items into a single total score. 
Cronbach’s α s were ≥ 0.92 at baseline. Test-retest ICCs were ≥ 0.95 (week 6 to 8). 
At baseline, moderate/strong correlations between PSI total score and DLQI item 1 
(skin symptoms; r= 0.69), DLQI symptoms and feelings domain (r= 0.66), and SF-36 
bodily pain (r= -0.58) supported convergent validity. PSI scores were significantly 
different (p< 0.001) among known PsO severity groups based on PASI (< 12 or ≥ 12), 
sPGA (0–1, 2–3, or 4–5), BSA (< 5, 5-10, or > 10), and DLQI (≤ 5 or > 5) at week 8 and 
12. At week 12, the PSI detected significant changes in PsO severity based on PASI 
(< 50; 50< 75; ≥ 75) and sPGA (0/1; ≥ 2), and showed good agreement (k≥ 0.66) between 
PSI response and PASI, sPGA, and DLQI responses. CONCLUSIONS: The PSI dem-
onstrated excellent reliability, validity, and ability to detect change in severity of 
psoriasis signs and symptoms.
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OBJECTIVES: Patients with Hidradenitis Suppurativa (HS) experience painful 
abscesses and nodules primarily in the skin flexures, along with other disease-
related impact and symptoms, which can further diminish their health-related 
quality of life. No HS-specific tools exist to assess those symptoms and impacts. 
We aimed to report the development and initial psychometric evaluation of the 
Hidradenitis Suppurativa Symptom Assessment (HSSA) and the Hidradenitis 
Suppurativa Impact Assessment (HSIA). METHODS: The HSSA and HSIA were 
developed based on a literature review and concept elicitation interviews with 
HS patients (n= 20). Following initial construction, the questionnaires were cog-
nitively debriefed among HS patients (n= 20) to test their readability and com-
prehensiveness. Next, the HSIA and HSSA were implemented in a multi-center, 
non-interventional study with HS patients (n= 40) to evaluate their item and scale 
OBJECTIVES: Pressure ulcers (PU) are distressing events, caused when skin and 
the underlying tissues are placed under pressure sufficient to impair blood supply. 
They can have a substantial impact on quality of life, and have significant resource 
implications, with extended hospital stays and significant staff time devoted to 
treating the more severe cases. Repositioning is a key prevention strategy, but 
can be resource intensive, leading to variation in practice. This economic analysis 
formed part of the National Institute for Health and Care Excellence (NICE) clinical 
guideline on PU prevention and management, and was conducted to identify the 
most cost-effect repositioning strategy for the prevention of PU. METHODS: The 
clinical inputs to the model were taken from the systematic review of clinical data 
conducted for the guideline. The model population was elderly people in a nurs-
ing home; this represents a group at high risk of developing a PU. The economic 
model was developed in consultation with members of the guideline development 
group (GDG), and took the perspective of the UK National Health Service. Outcomes 
were expressed as costs and quality adjusted life years (QALYs). RESULTS: Despite 
being marginally more clinically effective, 2 and 4 hourly repositioning is not cost-
effective (compared to 4 hourly repositioning) for this high risk group of patients 
at a cost-effectiveness threshold of £20,000 per QALY. The ICER was £1,854,070 per 
QALY. CONCLUSIONS: 2 and 4 hourly repositioning is not cost-effective (compared 
to 4 hourly repositioning) in the UK for the group of patients analyzed here. These 
results were used to inform the guideline recommendations. FUNDING: This work 
was undertaken by the National Clinical Guideline Centre, which received funding 
from NICE. The views expressed in this publication are those of the authors and 
not necessarily of the institute.
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OBJECTIVES: To evaluate the cost-effectiveness of ranibizumab compared with 
aflibercept for the treatment of neovascular (wet) age-related macular degenera-
tion AMD from the UK healthcare provider perspective. METHODS: A patient 
simulation model was developed with best corrected visual acuity (BCVA) used 
as a marker of disease progression. Baseline patient characteristics were based 
on the EXCITE Phase III study. Change in BCVA for Year 1 and Year 2 were based 
on a network meta-analysis. Beyond Year 2 or after treatment discontinuation, 
BCVA in the treated eye was modelled using natural history data for wet AMD 
patients. Natural history data for the general population was used to model the 
untreated eye. BCVA change in each eye was modelled independently. A prob-
ability of developing bilateral disease was applied throughout the model. Utility 
values were estimated by a regression analysis of BCVA in the better-seeing 
eye (BSE) and in the worse-seeing eye (WSE). Three scenarios based on differ-
ent treatment and monitoring schedules were analyzed; pro-re-nata (PRN), treat 
and extend (T&E), observe and extend (O&E). The model assumed that 50% of 
patients were treated via one-stop monitoring, and 50% with two-stop moni-
toring. RESULTS: The difference in lifetime costs associated with ranibizumab 
(0.5mg) ranges from a saving of £22 with T&E regimen, to a reduction of £7,416 
with a PRN regimen. In addition, ranibizumab was associated with lifetime 
quality-adjusted life years (QALYs) of 5.07 compared with 5.06 for aflibercept 
and as a consequence dominated aflibercept. Probabilistic sensitivity analysis 
suggests that the probability of ranibizumab (0.5mg) being cost-effective with 
a T&E regimen is 27% at a £20,000 threshold, and 30% at a £30,000 threshold. 
With a PRN regimen, the probability of cost-effectiveness was 86% at a £20,000 
threshold and 86% at a £30,000 threshold. CONCLUSIONS: Ranibizumab domi-
nates aflibercept for patients with neovascular AMD irrespective of treatment 
regimen.
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OBJECTIVES: The World Health Organization reports that India’s rates of debili-
tating hearing loss are more than double rates in Europe and North America. 
With a population over 1.25 billion, India’s burden of hearing loss is extremely 
high. The cochlear implant (CI) is a highly effective treatment, providing some 
hearing to the deaf; however, CI use is extremely limited in India due to device 
cost, low incomes, limited medical and audiology expertise, and lack of aware-
ness. The objective of this study is to estimate the cost of a CI device whose use 
would be considered cost-effective in India for 1-year old children—the subgroup 
with the greatest utility gain. METHODS: The lifetime QALYs gained and payer 
costs are estimated based on a literature review and Indian life tables, and are 
discounted at 3% annually. The threshold incremental cost-utility ratio (ICUR) is 
considered at 3x, 2x, and 1x per capita gross domestic product (PCGDP). Given 
cost estimates of pre-implant evaluations, surgery costs, post-implant audiol-
ogy care, device upkeep, and the medical costs of complications and revision 
surgery, the ICUR equation is solved to determine the maximum cost-effective 
device cost. RESULTS: The health utility gain for a CI device implanted in a 1-year 
old was estimated at 0.36 with confidence interval (0.29; 0.43). Lifetime QALY 
gain was 9.28 (7.47; 11.03). Lifetime costs excluding the device cost were $14,895 
($10,639--$20,853). Given a PCGDP of $1,666, the cost-effectiveness willingness-
to-pay thresholds for maximum device cost for 3x, 2x and 1x PCGDP were $24,664 
($10,973; $36,664), $11,477 ($36; $20,896) and -$1,709 (-$10,242; $5,129), respec-
tively. The current minimum price of the device is ~$12,000. CONCLUSIONS: CIs 
in 1-year olds would be cost-effective in India based on a threshold of 3x or 2x 
PCGDP, but medical and device costs would have to be reduced to meet a 1x PCGDP 
threshold.
